Seagen Shares Move Higher; Jim Cramer Tweets ‘loving Joe T’s choice of Seagen on @ScottWapnerCNBC, @HalftimeReport @terranovajoe’
https://twitter.com/jimcramer/status/1429842275564146690
Seagen Bets On China’s ADC In $2.6B Cancer Deal
Seagen Inc (NASDAQ:SGEN) and RemeGen Co Ltd have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin. For $200…
Seagen, RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin; Seagen to Make $200M Upfront Payment to License Rights to Disitamab Vedotin
Seagen Inc. (Nasdaq: SGEN) and RemeGen Co., Ltd. (9995.HK), a leading innovative biopharmaceutical company in China, today announced that the two companies have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC.
Earnings Scheduled For July 29, 2021
Companies Reporting Before The Bell
• Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter.
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.
Morgan Stanley Maintains Equal-Weight on Seagen, Lowers Price Target to $167
Morgan Stanley analyst Matthew Harrison maintains Seagen (NASDAQ:SGEN) with a Equal-Weight and lowers the price target from $173 to $167.
Astellas – Seagen’s PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer
The FDA granted full approval and a label expansion for Seagen Inc (NASDAQ:SGEN) – Astellas Pharma Inc’s (OTC:ALPMF) PADCEV to treat patients with advanced or…
Seagen Says FDA Grants Regular Approval, Expands Indication For PADCEV For Patients With Locally Advanced Or Metastatic Urothelial Cancer
Seagen Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the U.S. Food and Drug Administration (FDA) granted
Updated Analysis Show Seagen’s Tukysa Extended Median OS to Two Years with Benefits Maintained in Breast Cancer
Seagen Inc (NASDAQ:SGEN) has announced that improvements in overall survival (OS) and progression-free survival (PFS) were maintained with long-term follow-up from…
Seagen Announces Long-Term Results from TUKYSA Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting
- Updated Analysis Shows Median Overall Survival for TUKYSA Arm Extended to Two Years, with Benefit Maintained Across All Prespecified Patient Subgroups in HER2CLIMB Trial -
- Results Further Support TUKYSA as